Cargando…

A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination

Patient: Female, 39-year-old Final Diagnosis: Immune thrombocytopenic purpura Symptoms: Purpuric skin lesions • thrombocytopenia Medication: — Clinical Procedure: None Specialty: Hematology • Immunology OBJECTIVE: Unusual clinical course BACKGROUND: Immune thrombocytopenic purpura (ITP) is an immune...

Descripción completa

Detalles Bibliográficos
Autores principales: King, Eleanor R., Towner, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311388/
https://www.ncbi.nlm.nih.gov/pubmed/34285180
http://dx.doi.org/10.12659/AJCR.931478
_version_ 1783728951311466496
author King, Eleanor R.
Towner, Elizabeth
author_facet King, Eleanor R.
Towner, Elizabeth
author_sort King, Eleanor R.
collection PubMed
description Patient: Female, 39-year-old Final Diagnosis: Immune thrombocytopenic purpura Symptoms: Purpuric skin lesions • thrombocytopenia Medication: — Clinical Procedure: None Specialty: Hematology • Immunology OBJECTIVE: Unusual clinical course BACKGROUND: Immune thrombocytopenic purpura (ITP) is an immune response that destroys platelets and increases the risk of bleeding, which can range from bruising to intracranial hemorrhage. ITP is a known complication of coronavirus disease 2019 (COVID-19). In the first studies of the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine, there were no reports of ITP and the incidence of serious adverse events (AEs) was low overall. Here, we present a case of ITP as a complication of the BNT162b2 mRNA COVID-19 vaccine. CASE REPORT: Three days after receiving a second dose of the BNT162b2 mRNA COVID-19 vaccine, a 39-year-old woman presented with a petechial rash on her trunk, legs, and arms, and fatigue and muscle aches. At the time of her hospital admission, her platelet count was 1000/µL. A peripheral smear showed profound thrombocytopenia. During the course of the patient’s hospitalization, she was treated with 2 units of platelets, 2 infusions of i.v. immunoglobulin, and i.v. methylprednisolone. Her platelet count increased to 92 000/µL on the day of discharge and she was prescribed a tapered dose of oral prednisone. One day later, her rash had resolved and her platelet count was 243 000/µL. The patient recovered completely with no complications. CONCLUSIONS: ITP should be considered a severe AE of the BNT162b2 mRNA COVID-19 vaccine. Knowing the early signs and symptoms of ITP will become increasingly important as more of the population receives this vaccine. Quick diagnosis and management are essential to avoid life-threatening bleeding.
format Online
Article
Text
id pubmed-8311388
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-83113882021-08-02 A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination King, Eleanor R. Towner, Elizabeth Am J Case Rep Articles Patient: Female, 39-year-old Final Diagnosis: Immune thrombocytopenic purpura Symptoms: Purpuric skin lesions • thrombocytopenia Medication: — Clinical Procedure: None Specialty: Hematology • Immunology OBJECTIVE: Unusual clinical course BACKGROUND: Immune thrombocytopenic purpura (ITP) is an immune response that destroys platelets and increases the risk of bleeding, which can range from bruising to intracranial hemorrhage. ITP is a known complication of coronavirus disease 2019 (COVID-19). In the first studies of the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine, there were no reports of ITP and the incidence of serious adverse events (AEs) was low overall. Here, we present a case of ITP as a complication of the BNT162b2 mRNA COVID-19 vaccine. CASE REPORT: Three days after receiving a second dose of the BNT162b2 mRNA COVID-19 vaccine, a 39-year-old woman presented with a petechial rash on her trunk, legs, and arms, and fatigue and muscle aches. At the time of her hospital admission, her platelet count was 1000/µL. A peripheral smear showed profound thrombocytopenia. During the course of the patient’s hospitalization, she was treated with 2 units of platelets, 2 infusions of i.v. immunoglobulin, and i.v. methylprednisolone. Her platelet count increased to 92 000/µL on the day of discharge and she was prescribed a tapered dose of oral prednisone. One day later, her rash had resolved and her platelet count was 243 000/µL. The patient recovered completely with no complications. CONCLUSIONS: ITP should be considered a severe AE of the BNT162b2 mRNA COVID-19 vaccine. Knowing the early signs and symptoms of ITP will become increasingly important as more of the population receives this vaccine. Quick diagnosis and management are essential to avoid life-threatening bleeding. International Scientific Literature, Inc. 2021-07-21 /pmc/articles/PMC8311388/ /pubmed/34285180 http://dx.doi.org/10.12659/AJCR.931478 Text en © Am J Case Rep, 2021 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Articles
King, Eleanor R.
Towner, Elizabeth
A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination
title A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination
title_full A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination
title_fullStr A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination
title_full_unstemmed A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination
title_short A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination
title_sort case of immune thrombocytopenia after bnt162b2 mrna covid-19 vaccination
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311388/
https://www.ncbi.nlm.nih.gov/pubmed/34285180
http://dx.doi.org/10.12659/AJCR.931478
work_keys_str_mv AT kingeleanorr acaseofimmunethrombocytopeniaafterbnt162b2mrnacovid19vaccination
AT townerelizabeth acaseofimmunethrombocytopeniaafterbnt162b2mrnacovid19vaccination
AT kingeleanorr caseofimmunethrombocytopeniaafterbnt162b2mrnacovid19vaccination
AT townerelizabeth caseofimmunethrombocytopeniaafterbnt162b2mrnacovid19vaccination